Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ELL-associated factor 1 (EAF1) is a transcription elongation factor that partners with the RNA polymerase II elongation factor ELL to modulate gene expression. It regulates transcription elongation, cellular proliferation, differentiation, and hormone signaling by forming multiprotein complexes and interacting with critical transcriptional machinery. EAF1 acts as a tumor suppressor in prostate epithelial cells, and its disruption is implicated in the development of acute myeloid leukemia via oncogenic fusion proteins (MLL-ELL and MLL-EAF1). EAF1 also plays a role in embryogenesis, cell fate decision, and erythroid differentiation through c-Myb and Wnt signaling pathways
No drugs directly target EAF1. In the context of disease, targeting EAF1 could theoretically impact transcriptional regulation, oncogenic fusion proteins, or cell differentiation—but mechanisms remain experimental or unknown.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ELL-associated factor 1 (EAF1).